S1316
Clinical - Urology
ESTRO 2026
and characteristics are collected from electronic medical records. The initial cohort of patients treated are included in this analysis. Results: To date, 20 patients have undergone SABR-prostate treatment in our unit, of whom 18 have consented to completing PROMs questionnaires. The mean age at time of treatment was 69 years. All patients had NCCN low or intermediate risk prostate cancer ( ≤ T2 on MRI; a presenting PSA <20 and Gleason grade ≤ 3+4). The mean PSA score at presentation was 8.35 mmol/L. Six of the 20 patients (30%) had been on androgen deprivation therapy prior to SABR. Of the 20 patients, 6 have completed their 12-week post SABR questionnaires. Of the subgroups in EPIC-26, bowel changes and urinary irritation were the most recorded patient reported outcomes. 66% of patients reported worsening of urinary irritation and obstructive symptoms at week-4 post SABR. 83% of men reported bowel frequency deterioration 4-weeks post SABR. No stool incontinence was reported by the Vaizey score. The IPSS score showed a mild increase in urinary toxicities from baseline, from an average of ‘mildly symptomatic’ to ‘moderately symptomatic’. The quality-of-life score of IPSS showed an acute decline, with return to baseline at 4-weeks. Conclusion: Although these results capture a small number of patients, at an early-stage post SABR treatment, the toxicity data is reassuring. As more patients are enrolled in SABR, we will be able to better understand short and long-term toxicities within our cohort of patients. Collecting the data prospectively is invaluable in understanding the timeline of early and late toxicities, and to help guide patient conversations and expectations before SABR treatment. References: 1) van As N, Griffin C, Tree A, et al. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N Engl J Med. 2024 Oct 17;391(15):1413-1425. doi:10.1056/NEJMoa2403365 2) Brand DH, Dodds D, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non- inferiority trial. Lancet Oncol. 2019;20(11):1531-1543.
Conclusion: SBRT for localized prostate cancer demonstrated excellent early biochemical control and a favorable safety profile. Results were consistent across risk groups and comparable to major trials, supporting SBRT as our standard institutional practice. Further follow-up is crucial to assess long-term control and late toxicity. Keywords: prostate cancer, sbrt, hypofractionation The effects of Stereotactic ablative body radiotherapy (SABR) on Patient Reported Outcomes toxicity scores in patients with prostate cancer in Sussex. Francesca M Wright, Angus J Robinson Oncology, University Hospitals Sussex, Brighton, United Kingdom Purpose/Objective: The PACE-B trial demonstrated benefits of prostate- SABR, with non-inferior efficacy compared to external Digital Poster 5013 beam radiotherapy (EBRT), less demanding for patients and oncology units, with acceptable equivalent toxicity rates (1). As one of the first trusts using this treatment in the South-East of England, we are prospectively collecting toxicity data in our patients treated with this radiotherapy extreme dose fractionation. Material/Methods: Patients are contacted when referred for SABR, and consented to complete the same Patient Reported Outcome Measures (PROMs) used in PACE-B trial (2). These include EPIC-26, Vaizey, IPSS and IEFF-5. PROMs are recorded at baseline and then assessed at the same time points as the trial. Patient demographics
doi:10.1016/S1470-2045(19)30411-0. Keywords: prospective, PROMs, SABR
Made with FlippingBook - Share PDF online